During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

JACKSON, Miss. (WJTV) – Registration is open for the University of Mississippi Medical Center (UMMC) Cancer Center and ...

The Texas Board of Paroles and Pardons has denied recommending clemency for Robert Roberson III one day before his scheduled ...

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Cervical cancer remains the most widespread cause of cancer death in women in the country, accounting for 12 percent of all cancer deaths recorded in Zimbabwe. Prostate cancer is the second most ...

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...

The connection between respiratory infections, chronic diseases like asthma, and the gut microbiome drives research toward ...

Cancer rates have been on the rise. Processed foods, a sedentary lifestyle, rising rates of obesity and alcohol use all ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...